Term ended Nov 5, 2024 · High confidence
20-year base term ended Nov 5, 2024
Held by Bausch + Lomb Ireland Limited
Filed Aug 19, 2013 as application 13/969,968 · Granted Dec 22, 2015
Base term, 20 years from filing
Today
Term ended Nov 5, 2024
2004
2026
Clock starts
Nov 5, 2004
Nov 5, 2004
Term ended
Nov 5, 2024
Nov 5, 2024
Granted
Dec 22, 2015
Dec 22, 2015
base term
after the term ends
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,745,460, US 9,248,126, to Nov 5, 2024. The term already ends on or before that date, so the cap shortened nothing.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
12
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 5, 2004, when application 10/982,463, the earliest non-provisional in its chain, was filed (this one was filed Aug 19, 2013) | Nov 5, 2024 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,745,460, US 9,248,126) | resolves to Nov 5, 2024, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Nov 5, 2024 | High confidence |
This family
| US 7,314,938 | In force Oct 2029 | Oct 2029 |
| US 7,745,460 | Term ended Nov 2024 | Nov 2024 |
| US 7,790,743 | Term ended Nov 2024 | Nov 2024 |
| US 7,928,122 | Term ended Nov 2024 | Nov 2024 |
| US 8,071,617 | Term ended Nov 2024 | Nov 2024 |
| US 7,989,626 | Term ended Nov 2024 | Nov 2024 |
| Application 13/223,557 | Abandoned not computed | not computed |
| US 9,216,174 | this patent Nov 2024 | Nov 2024 |
8 of 12 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 8, 2017 Reel 42646, frame 531 | Shen, Wang; Barr, Kenneth; Oslob, Johan D.; Zhong, Min | Sunesis Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jun 8, 2017 Reel 42646, frame 606 | Sunesis Pharmaceuticals, Inc. | Sarcode Corporation | Assignment of Assignor's Interest |
| Jun 8, 2017 Reel 42735, frame 879 | Sarcode Corporation | Sarcode Bioscience Inc. | Change of Name |
| May 30, 2019 Reel 49315, frame 108 | Sarcode Bioscience Inc. | Silicon Valley Bank | Security Agreement |
| May 30, 2019 Reel 49315, frame 238 | Silicon Valley Bank | Sarcode Bioscience Inc. | Release of Security Interest |
| Oct 31, 2019 Reel 50900, frame 268 | Sarcode Bioscience Inc. | Novartis AG | Assignment of Assignor's Interest |
| Oct 22, 2020 Reel 54134, frame 708 | Novartis AG | Novartis Pharmaceuticals Corporation | Assignment of Assignor's Interest |
| Dec 6, 2023 Reel 65789, frame 853 | Novartis Pharmaceuticals Corporation | Bausch + Lomb Ireland Limited | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,745,460, US 9,248,126, ends no earlier than this term, so it caps nothing.
Citations
28
later US patents cite this one
That is top 25% of utility patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.